Nautilus Biotechnology Stock Buy Hold or Sell Recommendation
| NAUT Stock | USD 1.11 0.05 4.72% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Nautilus Biotechnology is 'Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Nautilus Biotechnology given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Nautilus Biotechnology, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Nautilus Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide. Note, we conduct extensive research on individual companies such as Nautilus and provide practical buy, sell, or hold advice based on investors' constraints. Nautilus Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Nautilus |
Execute Nautilus Biotechnology Buy or Sell Advice
The Nautilus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Nautilus Biotechnology. Macroaxis does not own or have any residual interests in Nautilus Biotechnology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Nautilus Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Nautilus Biotechnology Trading Alerts and Improvement Suggestions
| Nautilus Biotechnology generated a negative expected return over the last 90 days | |
| Nautilus Biotechnology may become a speculative penny stock | |
| Nautilus Biotechnology has high historical volatility and very poor performance | |
| Net Loss for the year was (70.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nautilus Biotechnology currently holds about 299.34 M in cash with (59.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Nautilus Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 33.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Akinsanya Karen of 14411 shares of Nautilus Biotechnology subject to Rule 16b-3 |
Nautilus Biotechnology Returns Distribution Density
The distribution of Nautilus Biotechnology's historical returns is an attempt to chart the uncertainty of Nautilus Biotechnology's future price movements. The chart of the probability distribution of Nautilus Biotechnology daily returns describes the distribution of returns around its average expected value. We use Nautilus Biotechnology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Nautilus Biotechnology returns is essential to provide solid investment advice for Nautilus Biotechnology.
| Mean Return | -0.9 | Value At Risk | -5.88 | Potential Upside | 5.70 | Standard Deviation | 4.20 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Nautilus Biotechnology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Nautilus Stock Institutional Investors
The Nautilus Biotechnology's institutional investors refer to entities that pool money to purchase Nautilus Biotechnology's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Tikvah Management Llc | 2024-12-31 | 726.9 K | Clarius Group, Llc | 2024-12-31 | 636.5 K | Botty Investors Llc | 2024-12-31 | 606.1 K | Northern Trust Corp | 2024-12-31 | 474.8 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 393.6 K | Wexford Capital Lp | 2024-12-31 | 325.2 K | Sentinel Trust Co Lba | 2024-12-31 | 255 K | Alyeska Investment Group, L.p. | 2024-12-31 | 253.5 K | Renaissance Technologies Corp | 2024-12-31 | 250.2 K | Perceptive Advisors Llc | 2024-12-31 | 12.6 M | Cercano Management Llc | 2024-12-31 | 7.2 M |
Nautilus Biotechnology Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 36.6M | 149.2M | (71.0M) | (95.1M) | 8.2M | 8.7M | |
| Free Cash Flow | (14.9M) | (41.5M) | (48.1M) | (54.2M) | (61.3M) | (64.3M) | |
| Other Non Cash Items | 295K | 320K | (890K) | (2.7M) | (2.0M) | (2.1M) | |
| Capital Expenditures | 921K | 2.3M | 2.3M | 2.4M | 2.1M | 1.7M | |
| Net Income | (15.6M) | (50.3M) | (57.9M) | (63.7M) | (70.8M) | (67.2M) | |
| End Period Cash Flow | 37.2M | 186.5M | 115.5M | 20.4M | 28.6M | 27.2M | |
| Investments | (24.4M) | (136.7M) | (25.7M) | (66.7M) | 66.3M | 69.6M | |
| Depreciation | 2.3M | 2.8M | 3.4M | 5.7M | 6.4M | 3.9M |
Nautilus Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Nautilus Biotechnology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Nautilus Biotechnology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Nautilus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.65 | |
β | Beta against Dow Jones | 2.41 | |
σ | Overall volatility | 4.31 | |
Ir | Information ratio | -0.19 |
Nautilus Biotechnology Volatility Alert
Nautilus Biotechnology exhibits very low volatility with skewness of -0.51 and kurtosis of 4.02. Nautilus Biotechnology is a potential penny stock. Although Nautilus Biotechnology may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Nautilus Biotechnology. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Nautilus instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Nautilus Biotechnology Fundamentals Vs Peers
Comparing Nautilus Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Nautilus Biotechnology's direct or indirect competition across all of the common fundamentals between Nautilus Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Nautilus Biotechnology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Nautilus Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Nautilus Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Nautilus Biotechnology to competition |
| Fundamentals | Nautilus Biotechnology | Peer Average |
| Return On Equity | -0.3 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Current Valuation | 40.61 M | 16.62 B |
| Shares Outstanding | 126.15 M | 571.82 M |
| Shares Owned By Insiders | 33.30 % | 10.09 % |
| Shares Owned By Institutions | 49.62 % | 39.21 % |
| Number Of Shares Shorted | 283.23 K | 4.71 M |
| Price To Book | 0.67 X | 9.51 X |
| EBITDA | (79.5 M) | 3.9 B |
| Net Income | (70.78 M) | 570.98 M |
| Cash And Equivalents | 299.34 M | 2.7 B |
| Cash Per Share | 2.40 X | 5.01 X |
| Total Debt | 30.48 M | 5.32 B |
| Debt To Equity | 0.09 % | 48.70 % |
| Current Ratio | 49.75 X | 2.16 X |
| Book Value Per Share | 1.66 X | 1.93 K |
| Cash Flow From Operations | (59.15 M) | 971.22 M |
| Short Ratio | 2.88 X | 4.00 X |
| Earnings Per Share | (0.56) X | 3.12 X |
| Target Price | 2.38 | |
| Number Of Employees | 155 | 18.84 K |
| Beta | 1.07 | -0.15 |
| Market Capitalization | 140.02 M | 19.03 B |
| Total Asset | 242.74 M | 29.47 B |
| Retained Earnings | (273.02 M) | 9.33 B |
| Working Capital | 125.19 M | 1.48 B |
| Net Asset | 242.74 M |
Note: Acquisition by Nazem Farzad of 45000 shares of Nautilus Biotechnology at 2.56 subject to Rule 16b-3 [view details]
Nautilus Biotechnology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Nautilus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Nautilus Biotechnology Buy or Sell Advice
When is the right time to buy or sell Nautilus Biotechnology? Buying financial instruments such as Nautilus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Nautilus Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Obamacare Thematic Idea Now
Obamacare
Health care services and providers including hospitals, clinics and nursing homes that hope to benefit from Obamacare program. The Obamacare theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.